Investor Update

Basel, 11 October 2011

Invitation to Late-stage pipeline event Monday, 7 November 2011

Monday, 7 November 2011

The Roche Investor Relations team would like to invite you to a Late-stage pipeline event that will take place in London on 7 November 2011 starting at 2pm local time.

The event will provide an opportunity to discuss clinical data and development plans for key late-stage compounds in the Roche development pipeline, including T-DM1 (HER2 franchise) for HER2-positive breast cancer and lebrikizumab (anti-IL13 antibody) for severe asthma.

Presenter:

• Hal Barron, Head of Global Product Development, Chief Medical Officer

Meeting information (download to my calendar)

• Date:7 November 2011
• Time: 1:30pm Registration
• 2:00pm Meeting start
• 3:30pm Meeting end
• Venue: CPC Venues, 4 Chiswell Street, London EC1Y 4UP, UK (map)

To register for the event please follow this link.

This presentation can be viewed through a live video webcast accessed via http://ir.roche.com.

Alternatively, dial in to the conference 10-15 min prior to the scheduled start using the following numbers (listen-only mode, no live-access to speakers):

• +41 (0) 91 610 5600 (Europe and ROW)
• +44 (0) 203 059 5862 (UK)
• +1 (1) 866 291 4166 (USA Toll Free)

Alternatively a live audio webcast can be accessed via http://ir.roche.com.

A replay of the conference call will be available one hour after the conference call, for 48 hours. Access is by dialing:

• +41 (0) 91 612 4330 (Europe and ROW) or
• +44 (0) 207 108 6233 (UK)
• +1 (1) 866 416 2558 (USA)

and will be asked to enter the ID 11854  followed by the # sign.

A replay of the webcast will be available on demand at http://ir.roche.com.